BEhavioral and Adherence Model for improving quality, health outcomes and cost-Effectiveness of healthcaRe

logo beamer 11






Innovative Medicines Initiative (IMI)


Horizon 2020 (H2020)

​The main objective of the Project is to create BEAMER, a disease-agnostic behavioral and adherence model for improving quality, health outcomes and cost-effectiveness of healthcare, through improving the quality of life of individuals, enhance healthcare accessibility and sustainability. The model will allow for tailoring to individual’s needs, using Real World Data captured from patients’ behaviors and health system information, transforming the way healthcare stakeholders engage with patients to optimise understanding of their condition and adherence levels throughout their patient journey.

BEAMER is driven by a set of Ontology, Epistemology and Methodology principles, supported by Artificial Intelligence, Natural Language Processing, and Machine Learning. BEAMER will optimize the disease-agnostic adherence model by real- life testing proof-of-concept in 18 different pilots in Norway, Spain, the Netherlands, Germany, Portugal, and Italy, including over 18,000 patients (3000 patients in each thematic area). BEAMER will be embodied in an open source European searchable database, continuously updated, validated and optimized by empirical evidence and new insights, available to all stakeholders and adaptable for future developments in healthcare. Finally, extensive efforts will be directed to develop and implement dissemination and communication activities that increase exploitation and sustainability of BEAMER.

The project will create a validated generalised model of significant and actionable factors affecting non-adherent behaviour. Disease-agnostic in nature, the model will help the project team to define the problem of non-adherence and provide guidance for health & care stakeholders as they develop and implement cost-effective digital tools and solutions. Interested in discovering how this model could contribute to better patient outcomes and reduced health system expenses? Keep on reading below!

Led by Pfizer, co-led by Merck KGaA and coordinated by PredictBy, the five-year project – brings together 27 European partners from academia, civil society and industry to jointly address the issue of non-adherence.